The Indian double mutant variant of coronavirus — B.1.617 — that has been termed as a variant of concern by the World Health Organization is moderately resistant to antibodies and is highly transmissible but has low severity among those who are vaccinated, a molecular study has said.
The study published by Indian SARS-CoV-2 Genomic Consortia along with the scientists of the Cambridge University in the UK in the bioRxiv, an open access preprint server, “Extensive vaccination will likely protect against moderate to severe disease and will reduce the transmission of B.1.617 given the in vitro neutralisation data we and others have presented.”
The B.1.617 variant first emerged in Maharashtra towards the end of 2020 and has spread throughout India and to at least 40 countries. The Indian mutation, the study says, has contributed to the epidemic wave in India. It found that the progression to severe disease and death was low in all studies.
The study titled SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies said that in absence of published data on transmissibility, it is predicted that the variant would have increased transmissibility even among those who are vaccinated or have pre-existing immunity. “It is unclear whether B.1.617 variants will prove more transmissible than B.1.1.7, also circulating in India and now globally dominant.”
“This spike confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies,” the study said referring to the Pfizer vaccine.
The study published by Indian SARS-CoV-2 Genomic Consortia along with the scientists of the Cambridge University in the UK in the bioRxiv, an open access preprint server, “Extensive vaccination will likely protect against moderate to severe disease and will reduce the transmission of B.1.617 given the in vitro neutralisation data we and others have presented.”
The B.1.617 variant first emerged in Maharashtra towards the end of 2020 and has spread throughout India and to at least 40 countries. The Indian mutation, the study says, has contributed to the epidemic wave in India. It found that the progression to severe disease and death was low in all studies.
The study titled SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies said that in absence of published data on transmissibility, it is predicted that the variant would have increased transmissibility even among those who are vaccinated or have pre-existing immunity. “It is unclear whether B.1.617 variants will prove more transmissible than B.1.1.7, also circulating in India and now globally dominant.”
“This spike confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies,” the study said referring to the Pfizer vaccine.

)